nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—CYP3A4—Everolimus—kidney cancer	0.132	0.293	CbGbCtD
Tadalafil—CYP3A4—Temsirolimus—kidney cancer	0.089	0.198	CbGbCtD
Tadalafil—CYP3A4—Pazopanib—kidney cancer	0.0468	0.104	CbGbCtD
Tadalafil—CYP3A4—Erlotinib—kidney cancer	0.0334	0.0741	CbGbCtD
Tadalafil—CYP3A4—Paclitaxel—kidney cancer	0.0306	0.0678	CbGbCtD
Tadalafil—CYP3A4—Sorafenib—kidney cancer	0.0271	0.0603	CbGbCtD
Tadalafil—CYP3A4—Vinblastine—kidney cancer	0.0268	0.0595	CbGbCtD
Tadalafil—CYP3A4—Vincristine—kidney cancer	0.0263	0.0585	CbGbCtD
Tadalafil—CYP3A4—Sunitinib—kidney cancer	0.022	0.0488	CbGbCtD
Tadalafil—CYP3A4—Doxorubicin—kidney cancer	0.0165	0.0366	CbGbCtD
Tadalafil—PDE11A—cGMP effects—KCNMA1—kidney cancer	0.00963	0.124	CbGpPWpGaD
Tadalafil—PDE5A—cGMP effects—KCNMA1—kidney cancer	0.00858	0.11	CbGpPWpGaD
Tadalafil—PDE11A—Nitric oxide stimulates guanylate cyclase—KCNMA1—kidney cancer	0.00765	0.0983	CbGpPWpGaD
Tadalafil—PDE5A—Nitric oxide stimulates guanylate cyclase—KCNMA1—kidney cancer	0.00682	0.0876	CbGpPWpGaD
Tadalafil—PDE11A—Platelet homeostasis—KCNMA1—kidney cancer	0.00298	0.0383	CbGpPWpGaD
Tadalafil—PDE5A—Platelet homeostasis—KCNMA1—kidney cancer	0.00266	0.0341	CbGpPWpGaD
Tadalafil—PDE11A—Platelet homeostasis—ITPR2—kidney cancer	0.00242	0.0311	CbGpPWpGaD
Tadalafil—PDE5A—Platelet homeostasis—ITPR2—kidney cancer	0.00215	0.0277	CbGpPWpGaD
Tadalafil—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.00177	0.0228	CbGpPWpGaD
Tadalafil—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.00111	0.0143	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—L1CAM—kidney cancer	0.00106	0.0137	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—OR4C13—kidney cancer	0.000969	0.0125	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—L1CAM—kidney cancer	0.000948	0.0122	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—OR4C13—kidney cancer	0.00088	0.0113	CbGpPWpGaD
Tadalafil—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000808	0.0104	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—ANXA2—kidney cancer	0.000806	0.0104	CbGpPWpGaD
Tadalafil—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000748	0.00961	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—ANXA2—kidney cancer	0.000718	0.00923	CbGpPWpGaD
Tadalafil—PDE11A—G alpha (s) signalling events—POMC—kidney cancer	0.000685	0.0088	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—KCNMA1—kidney cancer	0.000668	0.00858	CbGpPWpGaD
Tadalafil—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000635	0.00815	CbGpPWpGaD
Tadalafil—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	0.000626	0.00805	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—KCNMA1—kidney cancer	0.000595	0.00765	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—GRB7—kidney cancer	0.000583	0.00748	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—ITPR2—kidney cancer	0.000542	0.00696	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—OR4C13—kidney cancer	0.00052	0.00668	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—GRB7—kidney cancer	0.000519	0.00667	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—ITPR2—kidney cancer	0.000483	0.0062	CbGpPWpGaD
Tadalafil—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000479	0.00615	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LATS1—kidney cancer	0.000442	0.00568	CbGpPWpGaD
Tadalafil—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000409	0.00526	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—AKAP13—kidney cancer	0.000403	0.00517	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IFNA1—kidney cancer	0.000398	0.00511	CbGpPWpGaD
Tadalafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000395	0.00508	CbGpPWpGaD
Tadalafil—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000379	0.00488	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AMER1—kidney cancer	0.000376	0.00483	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IFNA2—kidney cancer	0.00037	0.00475	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKAP13—kidney cancer	0.000366	0.0047	CbGpPWpGaD
Tadalafil—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.00036	0.00462	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IFNA1—kidney cancer	0.000354	0.00455	CbGpPWpGaD
Tadalafil—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000345	0.00443	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ITPR2—kidney cancer	0.000342	0.0044	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IGF2—kidney cancer	0.000333	0.00428	CbGpPWpGaD
Tadalafil—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000331	0.00425	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IFNA2—kidney cancer	0.00033	0.00424	CbGpPWpGaD
Tadalafil—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000318	0.00409	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GPC3—kidney cancer	0.000315	0.00405	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CER1—kidney cancer	0.000315	0.00405	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000314	0.00403	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—ITPR2—kidney cancer	0.000311	0.00399	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000304	0.00391	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IGF2—kidney cancer	0.000297	0.00381	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ANXA1—kidney cancer	0.000287	0.00368	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SFRP2—kidney cancer	0.000268	0.00344	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—ANXA1—kidney cancer	0.00026	0.00335	CbGpPWpGaD
Tadalafil—Vertigo—Paclitaxel—kidney cancer	0.000254	0.000539	CcSEcCtD
Tadalafil—Syncope—Paclitaxel—kidney cancer	0.000254	0.000538	CcSEcCtD
Tadalafil—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000254	0.000537	CcSEcCtD
Tadalafil—Hypersensitivity—Sunitinib—kidney cancer	0.000253	0.000537	CcSEcCtD
Tadalafil—Pruritus—Sorafenib—kidney cancer	0.000253	0.000535	CcSEcCtD
Tadalafil—Vomiting—Erlotinib—kidney cancer	0.000252	0.000535	CcSEcCtD
Tadalafil—Erythema multiforme—Capecitabine—kidney cancer	0.000252	0.000534	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000251	0.000532	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Vincristine—kidney cancer	0.000251	0.000532	CcSEcCtD
Tadalafil—Fatigue—Vincristine—kidney cancer	0.000251	0.000531	CcSEcCtD
Tadalafil—Rash—Erlotinib—kidney cancer	0.00025	0.00053	CcSEcCtD
Tadalafil—Dermatitis—Erlotinib—kidney cancer	0.00025	0.00053	CcSEcCtD
Tadalafil—Palpitations—Paclitaxel—kidney cancer	0.00025	0.00053	CcSEcCtD
Tadalafil—Insomnia—Gemcitabine—kidney cancer	0.000249	0.000529	CcSEcCtD
Tadalafil—Eye disorder—Capecitabine—kidney cancer	0.000249	0.000528	CcSEcCtD
Tadalafil—Headache—Erlotinib—kidney cancer	0.000249	0.000527	CcSEcCtD
Tadalafil—Tinnitus—Capecitabine—kidney cancer	0.000249	0.000527	CcSEcCtD
Tadalafil—Loss of consciousness—Paclitaxel—kidney cancer	0.000249	0.000527	CcSEcCtD
Tadalafil—Pain—Vincristine—kidney cancer	0.000249	0.000527	CcSEcCtD
Tadalafil—Constipation—Vincristine—kidney cancer	0.000249	0.000527	CcSEcCtD
Tadalafil—Pain in extremity—Doxorubicin—kidney cancer	0.000248	0.000527	CcSEcCtD
Tadalafil—Paraesthesia—Gemcitabine—kidney cancer	0.000248	0.000525	CcSEcCtD
Tadalafil—Flushing—Capecitabine—kidney cancer	0.000247	0.000524	CcSEcCtD
Tadalafil—Cardiac disorder—Capecitabine—kidney cancer	0.000247	0.000524	CcSEcCtD
Tadalafil—Cough—Paclitaxel—kidney cancer	0.000247	0.000523	CcSEcCtD
Tadalafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000247	0.00317	CbGpPWpGaD
Tadalafil—Asthenia—Sunitinib—kidney cancer	0.000247	0.000523	CcSEcCtD
Tadalafil—Dyspnoea—Gemcitabine—kidney cancer	0.000246	0.000521	CcSEcCtD
Tadalafil—Nausea—Vinblastine—kidney cancer	0.000245	0.00052	CcSEcCtD
Tadalafil—Somnolence—Gemcitabine—kidney cancer	0.000245	0.00052	CcSEcCtD
Tadalafil—Convulsion—Paclitaxel—kidney cancer	0.000245	0.000519	CcSEcCtD
Tadalafil—Migraine—Doxorubicin—kidney cancer	0.000245	0.000518	CcSEcCtD
Tadalafil—Nausea—Everolimus—kidney cancer	0.000244	0.000518	CcSEcCtD
Tadalafil—Diarrhoea—Sorafenib—kidney cancer	0.000244	0.000518	CcSEcCtD
Tadalafil—Hypertension—Paclitaxel—kidney cancer	0.000244	0.000518	CcSEcCtD
Tadalafil—Pruritus—Sunitinib—kidney cancer	0.000243	0.000515	CcSEcCtD
Tadalafil—Angiopathy—Capecitabine—kidney cancer	0.000242	0.000513	CcSEcCtD
Tadalafil—Immune system disorder—Capecitabine—kidney cancer	0.000241	0.00051	CcSEcCtD
Tadalafil—Arthralgia—Paclitaxel—kidney cancer	0.000241	0.00051	CcSEcCtD
Tadalafil—Chest pain—Paclitaxel—kidney cancer	0.000241	0.00051	CcSEcCtD
Tadalafil—Myalgia—Paclitaxel—kidney cancer	0.000241	0.00051	CcSEcCtD
Tadalafil—Mediastinal disorder—Capecitabine—kidney cancer	0.00024	0.000509	CcSEcCtD
Tadalafil—Face oedema—Doxorubicin—kidney cancer	0.00024	0.000508	CcSEcCtD
Tadalafil—Hypersensitivity—Dactinomycin—kidney cancer	0.00024	0.000508	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000239	0.000507	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000238	0.000505	CcSEcCtD
Tadalafil—Discomfort—Paclitaxel—kidney cancer	0.000238	0.000504	CcSEcCtD
Tadalafil—Fatigue—Gemcitabine—kidney cancer	0.000238	0.000504	CcSEcCtD
Tadalafil—Gastrointestinal pain—Vincristine—kidney cancer	0.000238	0.000504	CcSEcCtD
Tadalafil—Dizziness—Sorafenib—kidney cancer	0.000236	0.000501	CcSEcCtD
Tadalafil—Constipation—Gemcitabine—kidney cancer	0.000236	0.0005	CcSEcCtD
Tadalafil—Pain—Gemcitabine—kidney cancer	0.000236	0.0005	CcSEcCtD
Tadalafil—Nausea—Erlotinib—kidney cancer	0.000236	0.0005	CcSEcCtD
Tadalafil—Dry mouth—Paclitaxel—kidney cancer	0.000235	0.000499	CcSEcCtD
Tadalafil—Diarrhoea—Sunitinib—kidney cancer	0.000235	0.000498	CcSEcCtD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000235	0.00302	CbGpPWpGaD
Tadalafil—Mental disorder—Capecitabine—kidney cancer	0.000234	0.000495	CcSEcCtD
Tadalafil—Asthenia—Dactinomycin—kidney cancer	0.000233	0.000495	CcSEcCtD
Tadalafil—Oedema—Paclitaxel—kidney cancer	0.000231	0.000489	CcSEcCtD
Tadalafil—Abdominal pain—Vincristine—kidney cancer	0.00023	0.000487	CcSEcCtD
Tadalafil—Liver function test abnormal—Doxorubicin—kidney cancer	0.000229	0.000486	CcSEcCtD
Tadalafil—Infection—Paclitaxel—kidney cancer	0.000229	0.000486	CcSEcCtD
Tadalafil—Dizziness—Sunitinib—kidney cancer	0.000227	0.000482	CcSEcCtD
Tadalafil—Shock—Paclitaxel—kidney cancer	0.000227	0.000481	CcSEcCtD
Tadalafil—Vomiting—Sorafenib—kidney cancer	0.000227	0.000481	CcSEcCtD
Tadalafil—Abdominal pain upper—Doxorubicin—kidney cancer	0.000227	0.000481	CcSEcCtD
Tadalafil—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000227	0.000481	CcSEcCtD
Tadalafil—Nervous system disorder—Paclitaxel—kidney cancer	0.000226	0.00048	CcSEcCtD
Tadalafil—Tachycardia—Paclitaxel—kidney cancer	0.000225	0.000478	CcSEcCtD
Tadalafil—Rash—Sorafenib—kidney cancer	0.000225	0.000477	CcSEcCtD
Tadalafil—Dermatitis—Sorafenib—kidney cancer	0.000225	0.000477	CcSEcCtD
Tadalafil—Back pain—Capecitabine—kidney cancer	0.000225	0.000476	CcSEcCtD
Tadalafil—Breast disorder—Doxorubicin—kidney cancer	0.000225	0.000476	CcSEcCtD
Tadalafil—Skin disorder—Paclitaxel—kidney cancer	0.000224	0.000475	CcSEcCtD
Tadalafil—Headache—Sorafenib—kidney cancer	0.000224	0.000474	CcSEcCtD
Tadalafil—Muscle spasms—Capecitabine—kidney cancer	0.000223	0.000473	CcSEcCtD
Tadalafil—Hyperhidrosis—Paclitaxel—kidney cancer	0.000223	0.000473	CcSEcCtD
Tadalafil—Diarrhoea—Dactinomycin—kidney cancer	0.000223	0.000472	CcSEcCtD
Tadalafil—Nasopharyngitis—Doxorubicin—kidney cancer	0.000222	0.000471	CcSEcCtD
Tadalafil—Gastritis—Doxorubicin—kidney cancer	0.00022	0.000466	CcSEcCtD
Tadalafil—Vision blurred—Capecitabine—kidney cancer	0.000219	0.000464	CcSEcCtD
Tadalafil—Vomiting—Sunitinib—kidney cancer	0.000218	0.000463	CcSEcCtD
Tadalafil—Rash—Sunitinib—kidney cancer	0.000217	0.000459	CcSEcCtD
Tadalafil—Dermatitis—Sunitinib—kidney cancer	0.000216	0.000459	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CASP2—kidney cancer	0.000216	0.00277	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKAP13—kidney cancer	0.000216	0.00277	CbGpPWpGaD
Tadalafil—Hypotension—Paclitaxel—kidney cancer	0.000216	0.000457	CcSEcCtD
Tadalafil—Headache—Sunitinib—kidney cancer	0.000215	0.000456	CcSEcCtD
Tadalafil—Dysphagia—Doxorubicin—kidney cancer	0.000215	0.000455	CcSEcCtD
Tadalafil—Influenza—Doxorubicin—kidney cancer	0.000215	0.000455	CcSEcCtD
Tadalafil—Hypersensitivity—Vincristine—kidney cancer	0.000214	0.000454	CcSEcCtD
Tadalafil—Nausea—Sorafenib—kidney cancer	0.000212	0.00045	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.00021	0.000446	CcSEcCtD
Tadalafil—Angina pectoris—Doxorubicin—kidney cancer	0.000209	0.000443	CcSEcCtD
Tadalafil—Insomnia—Paclitaxel—kidney cancer	0.000209	0.000443	CcSEcCtD
Tadalafil—Vertigo—Capecitabine—kidney cancer	0.000209	0.000442	CcSEcCtD
Tadalafil—Asthenia—Vincristine—kidney cancer	0.000209	0.000442	CcSEcCtD
Tadalafil—Syncope—Capecitabine—kidney cancer	0.000208	0.000441	CcSEcCtD
Tadalafil—Paraesthesia—Paclitaxel—kidney cancer	0.000207	0.000439	CcSEcCtD
Tadalafil—Vomiting—Dactinomycin—kidney cancer	0.000207	0.000438	CcSEcCtD
Tadalafil—Bronchitis—Doxorubicin—kidney cancer	0.000207	0.000438	CcSEcCtD
Tadalafil—Dyspnoea—Paclitaxel—kidney cancer	0.000206	0.000436	CcSEcCtD
Tadalafil—Somnolence—Paclitaxel—kidney cancer	0.000205	0.000435	CcSEcCtD
Tadalafil—Palpitations—Capecitabine—kidney cancer	0.000205	0.000435	CcSEcCtD
Tadalafil—Rash—Dactinomycin—kidney cancer	0.000205	0.000435	CcSEcCtD
Tadalafil—Nausea—Sunitinib—kidney cancer	0.000204	0.000433	CcSEcCtD
Tadalafil—Loss of consciousness—Capecitabine—kidney cancer	0.000204	0.000432	CcSEcCtD
Tadalafil—Dyspepsia—Paclitaxel—kidney cancer	0.000203	0.000431	CcSEcCtD
Tadalafil—Cough—Capecitabine—kidney cancer	0.000203	0.000429	CcSEcCtD
Tadalafil—Hypertension—Capecitabine—kidney cancer	0.0002	0.000425	CcSEcCtD
Tadalafil—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.0002	0.000423	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000199	0.000422	CcSEcCtD
Tadalafil—Fatigue—Paclitaxel—kidney cancer	0.000199	0.000422	CcSEcCtD
Tadalafil—Diarrhoea—Vincristine—kidney cancer	0.000199	0.000421	CcSEcCtD
Tadalafil—Asthenia—Gemcitabine—kidney cancer	0.000198	0.000419	CcSEcCtD
Tadalafil—Arthralgia—Capecitabine—kidney cancer	0.000198	0.000419	CcSEcCtD
Tadalafil—Myalgia—Capecitabine—kidney cancer	0.000198	0.000419	CcSEcCtD
Tadalafil—Chest pain—Capecitabine—kidney cancer	0.000198	0.000419	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—GRB7—kidney cancer	0.000197	0.00254	CbGpPWpGaD
Tadalafil—Constipation—Paclitaxel—kidney cancer	0.000197	0.000418	CcSEcCtD
Tadalafil—Pain—Paclitaxel—kidney cancer	0.000197	0.000418	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000196	0.000416	CcSEcCtD
Tadalafil—Discomfort—Capecitabine—kidney cancer	0.000195	0.000414	CcSEcCtD
Tadalafil—Pruritus—Gemcitabine—kidney cancer	0.000195	0.000413	CcSEcCtD
Tadalafil—Dry mouth—Capecitabine—kidney cancer	0.000193	0.00041	CcSEcCtD
Tadalafil—Nausea—Dactinomycin—kidney cancer	0.000193	0.00041	CcSEcCtD
Tadalafil—Dizziness—Vincristine—kidney cancer	0.000192	0.000407	CcSEcCtD
Tadalafil—Infestation NOS—Doxorubicin—kidney cancer	0.000191	0.000406	CcSEcCtD
Tadalafil—Infestation—Doxorubicin—kidney cancer	0.000191	0.000406	CcSEcCtD
Tadalafil—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.00019	0.000402	CcSEcCtD
Tadalafil—Oedema—Capecitabine—kidney cancer	0.000189	0.000402	CcSEcCtD
Tadalafil—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000189	0.0004	CcSEcCtD
Tadalafil—Diarrhoea—Gemcitabine—kidney cancer	0.000189	0.0004	CcSEcCtD
Tadalafil—Renal failure—Doxorubicin—kidney cancer	0.000188	0.000399	CcSEcCtD
Tadalafil—Infection—Capecitabine—kidney cancer	0.000188	0.000399	CcSEcCtD
Tadalafil—Shock—Capecitabine—kidney cancer	0.000186	0.000395	CcSEcCtD
Tadalafil—Urinary tract infection—Doxorubicin—kidney cancer	0.000186	0.000394	CcSEcCtD
Tadalafil—Conjunctivitis—Doxorubicin—kidney cancer	0.000186	0.000394	CcSEcCtD
Tadalafil—Nervous system disorder—Capecitabine—kidney cancer	0.000186	0.000394	CcSEcCtD
Tadalafil—Tachycardia—Capecitabine—kidney cancer	0.000185	0.000392	CcSEcCtD
Tadalafil—Vomiting—Vincristine—kidney cancer	0.000185	0.000392	CcSEcCtD
Tadalafil—Skin disorder—Capecitabine—kidney cancer	0.000184	0.00039	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ITPR2—kidney cancer	0.000184	0.00236	CbGpPWpGaD
Tadalafil—Sweating—Doxorubicin—kidney cancer	0.000184	0.000389	CcSEcCtD
Tadalafil—Urticaria—Paclitaxel—kidney cancer	0.000183	0.000389	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—RAF1—kidney cancer	0.000183	0.00236	CbGpPWpGaD
Tadalafil—Rash—Vincristine—kidney cancer	0.000183	0.000388	CcSEcCtD
Tadalafil—Hyperhidrosis—Capecitabine—kidney cancer	0.000183	0.000388	CcSEcCtD
Tadalafil—Dermatitis—Vincristine—kidney cancer	0.000183	0.000388	CcSEcCtD
Tadalafil—Haematuria—Doxorubicin—kidney cancer	0.000183	0.000387	CcSEcCtD
Tadalafil—Abdominal pain—Paclitaxel—kidney cancer	0.000182	0.000387	CcSEcCtD
Tadalafil—Headache—Vincristine—kidney cancer	0.000182	0.000386	CcSEcCtD
Tadalafil—Epistaxis—Doxorubicin—kidney cancer	0.000181	0.000383	CcSEcCtD
Tadalafil—Hypotension—Capecitabine—kidney cancer	0.000177	0.000375	CcSEcCtD
Tadalafil—Vomiting—Gemcitabine—kidney cancer	0.000175	0.000372	CcSEcCtD
Tadalafil—Rash—Gemcitabine—kidney cancer	0.000174	0.000368	CcSEcCtD
Tadalafil—Dermatitis—Gemcitabine—kidney cancer	0.000174	0.000368	CcSEcCtD
Tadalafil—Haemoglobin—Doxorubicin—kidney cancer	0.000173	0.000366	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000173	0.00222	CbGpPWpGaD
Tadalafil—Headache—Gemcitabine—kidney cancer	0.000173	0.000366	CcSEcCtD
Tadalafil—Nausea—Vincristine—kidney cancer	0.000173	0.000366	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000173	0.000366	CcSEcCtD
Tadalafil—Rhinitis—Doxorubicin—kidney cancer	0.000172	0.000365	CcSEcCtD
Tadalafil—Haemorrhage—Doxorubicin—kidney cancer	0.000172	0.000364	CcSEcCtD
Tadalafil—Insomnia—Capecitabine—kidney cancer	0.000171	0.000363	CcSEcCtD
Tadalafil—Hypoaesthesia—Doxorubicin—kidney cancer	0.000171	0.000362	CcSEcCtD
Tadalafil—Pharyngitis—Doxorubicin—kidney cancer	0.000171	0.000362	CcSEcCtD
Tadalafil—Paraesthesia—Capecitabine—kidney cancer	0.00017	0.000361	CcSEcCtD
Tadalafil—Hypersensitivity—Paclitaxel—kidney cancer	0.00017	0.00036	CcSEcCtD
Tadalafil—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	0.00017	0.00218	CbGpPWpGaD
Tadalafil—Urinary tract disorder—Doxorubicin—kidney cancer	0.00017	0.00036	CcSEcCtD
Tadalafil—Oedema peripheral—Doxorubicin—kidney cancer	0.000169	0.000359	CcSEcCtD
Tadalafil—Connective tissue disorder—Doxorubicin—kidney cancer	0.000169	0.000358	CcSEcCtD
Tadalafil—Dyspnoea—Capecitabine—kidney cancer	0.000169	0.000358	CcSEcCtD
Tadalafil—Urethral disorder—Doxorubicin—kidney cancer	0.000168	0.000357	CcSEcCtD
Tadalafil—Dyspepsia—Capecitabine—kidney cancer	0.000167	0.000353	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	0.000167	0.00214	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CTNNA1—kidney cancer	0.000166	0.00214	CbGpPWpGaD
Tadalafil—Asthenia—Paclitaxel—kidney cancer	0.000166	0.000351	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—HSPB1—kidney cancer	0.000166	0.00213	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EIF4EBP1—kidney cancer	0.000166	0.00213	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IL2—kidney cancer	0.000164	0.00211	CbGpPWpGaD
Tadalafil—Nausea—Gemcitabine—kidney cancer	0.000164	0.000347	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000164	0.000347	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—RAF1—kidney cancer	0.000163	0.0021	CbGpPWpGaD
Tadalafil—Fatigue—Capecitabine—kidney cancer	0.000163	0.000346	CcSEcCtD
Tadalafil—Pruritus—Paclitaxel—kidney cancer	0.000163	0.000346	CcSEcCtD
Tadalafil—Erythema multiforme—Doxorubicin—kidney cancer	0.000163	0.000344	CcSEcCtD
Tadalafil—Constipation—Capecitabine—kidney cancer	0.000162	0.000343	CcSEcCtD
Tadalafil—Pain—Capecitabine—kidney cancer	0.000162	0.000343	CcSEcCtD
Tadalafil—Eye disorder—Doxorubicin—kidney cancer	0.000161	0.00034	CcSEcCtD
Tadalafil—Tinnitus—Doxorubicin—kidney cancer	0.00016	0.00034	CcSEcCtD
Tadalafil—Flushing—Doxorubicin—kidney cancer	0.00016	0.000338	CcSEcCtD
Tadalafil—Cardiac disorder—Doxorubicin—kidney cancer	0.00016	0.000338	CcSEcCtD
Tadalafil—Diarrhoea—Paclitaxel—kidney cancer	0.000158	0.000335	CcSEcCtD
Tadalafil—Angiopathy—Doxorubicin—kidney cancer	0.000156	0.000331	CcSEcCtD
Tadalafil—Immune system disorder—Doxorubicin—kidney cancer	0.000155	0.000329	CcSEcCtD
Tadalafil—Gastrointestinal pain—Capecitabine—kidney cancer	0.000155	0.000328	CcSEcCtD
Tadalafil—Mediastinal disorder—Doxorubicin—kidney cancer	0.000155	0.000328	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PSMD7—kidney cancer	0.000154	0.00198	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TSC1—kidney cancer	0.000154	0.00198	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ANXA1—kidney cancer	0.000154	0.00198	CbGpPWpGaD
Tadalafil—Dizziness—Paclitaxel—kidney cancer	0.000153	0.000324	CcSEcCtD
Tadalafil—Mental disorder—Doxorubicin—kidney cancer	0.000151	0.000319	CcSEcCtD
Tadalafil—Urticaria—Capecitabine—kidney cancer	0.00015	0.000319	CcSEcCtD
Tadalafil—Abdominal pain—Capecitabine—kidney cancer	0.00015	0.000317	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—FLT1—kidney cancer	0.000149	0.00191	CbGpPWpGaD
Tadalafil—Vomiting—Paclitaxel—kidney cancer	0.000147	0.000311	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—IL2—kidney cancer	0.000147	0.00188	CbGpPWpGaD
Tadalafil—Rash—Paclitaxel—kidney cancer	0.000146	0.000308	CcSEcCtD
Tadalafil—Dermatitis—Paclitaxel—kidney cancer	0.000145	0.000308	CcSEcCtD
Tadalafil—Back pain—Doxorubicin—kidney cancer	0.000145	0.000307	CcSEcCtD
Tadalafil—Headache—Paclitaxel—kidney cancer	0.000145	0.000307	CcSEcCtD
Tadalafil—Muscle spasms—Doxorubicin—kidney cancer	0.000144	0.000305	CcSEcCtD
Tadalafil—Vision blurred—Doxorubicin—kidney cancer	0.000141	0.000299	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—POMC—kidney cancer	0.000141	0.00181	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—VEGFA—kidney cancer	0.00014	0.00179	CbGpPWpGaD
Tadalafil—Hypersensitivity—Capecitabine—kidney cancer	0.00014	0.000296	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PAK1—kidney cancer	0.000138	0.00177	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—JUNB—kidney cancer	0.000138	0.00177	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000137	0.00176	CbGpPWpGaD
Tadalafil—Nausea—Paclitaxel—kidney cancer	0.000137	0.000291	CcSEcCtD
Tadalafil—Asthenia—Capecitabine—kidney cancer	0.000136	0.000288	CcSEcCtD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000135	0.00174	CbGpPWpGaD
Tadalafil—Vertigo—Doxorubicin—kidney cancer	0.000134	0.000285	CcSEcCtD
Tadalafil—Syncope—Doxorubicin—kidney cancer	0.000134	0.000284	CcSEcCtD
Tadalafil—Pruritus—Capecitabine—kidney cancer	0.000134	0.000284	CcSEcCtD
Tadalafil—Palpitations—Doxorubicin—kidney cancer	0.000132	0.00028	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—MAPK3—kidney cancer	0.000132	0.0017	CbGpPWpGaD
Tadalafil—Loss of consciousness—Doxorubicin—kidney cancer	0.000132	0.000279	CcSEcCtD
Tadalafil—Cough—Doxorubicin—kidney cancer	0.000131	0.000277	CcSEcCtD
Tadalafil—Convulsion—Doxorubicin—kidney cancer	0.00013	0.000275	CcSEcCtD
Tadalafil—Diarrhoea—Capecitabine—kidney cancer	0.00013	0.000275	CcSEcCtD
Tadalafil—Hypertension—Doxorubicin—kidney cancer	0.000129	0.000274	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—POMC—kidney cancer	0.000128	0.00164	CbGpPWpGaD
Tadalafil—Arthralgia—Doxorubicin—kidney cancer	0.000127	0.00027	CcSEcCtD
Tadalafil—Chest pain—Doxorubicin—kidney cancer	0.000127	0.00027	CcSEcCtD
Tadalafil—Myalgia—Doxorubicin—kidney cancer	0.000127	0.00027	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000127	0.000268	CcSEcCtD
Tadalafil—Discomfort—Doxorubicin—kidney cancer	0.000126	0.000267	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—MAPK1—kidney cancer	0.000126	0.00162	CbGpPWpGaD
Tadalafil—Dizziness—Capecitabine—kidney cancer	0.000125	0.000266	CcSEcCtD
Tadalafil—Dry mouth—Doxorubicin—kidney cancer	0.000125	0.000264	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—VEGFA—kidney cancer	0.000125	0.0016	CbGpPWpGaD
Tadalafil—Oedema—Doxorubicin—kidney cancer	0.000122	0.000259	CcSEcCtD
Tadalafil—Infection—Doxorubicin—kidney cancer	0.000121	0.000257	CcSEcCtD
Tadalafil—Vomiting—Capecitabine—kidney cancer	0.00012	0.000255	CcSEcCtD
Tadalafil—Shock—Doxorubicin—kidney cancer	0.00012	0.000255	CcSEcCtD
Tadalafil—Nervous system disorder—Doxorubicin—kidney cancer	0.00012	0.000254	CcSEcCtD
Tadalafil—Rash—Capecitabine—kidney cancer	0.000119	0.000253	CcSEcCtD
Tadalafil—Dermatitis—Capecitabine—kidney cancer	0.000119	0.000253	CcSEcCtD
Tadalafil—Tachycardia—Doxorubicin—kidney cancer	0.000119	0.000253	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—KRAS—kidney cancer	0.000119	0.00153	CbGpPWpGaD
Tadalafil—Headache—Capecitabine—kidney cancer	0.000119	0.000252	CcSEcCtD
Tadalafil—Skin disorder—Doxorubicin—kidney cancer	0.000119	0.000251	CcSEcCtD
Tadalafil—Hyperhidrosis—Doxorubicin—kidney cancer	0.000118	0.00025	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—MAPK3—kidney cancer	0.000118	0.00151	CbGpPWpGaD
Tadalafil—Hypotension—Doxorubicin—kidney cancer	0.000114	0.000242	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—IGF2—kidney cancer	0.000113	0.00145	CbGpPWpGaD
Tadalafil—Nausea—Capecitabine—kidney cancer	0.000113	0.000238	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CDKN2B—kidney cancer	0.000112	0.00144	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—MAPK1—kidney cancer	0.000112	0.00144	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000111	0.00143	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000111	0.000236	CcSEcCtD
Tadalafil—Insomnia—Doxorubicin—kidney cancer	0.00011	0.000234	CcSEcCtD
Tadalafil—Paraesthesia—Doxorubicin—kidney cancer	0.00011	0.000232	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—IGF1R—kidney cancer	0.000109	0.0014	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CA—kidney cancer	0.000109	0.0014	CbGpPWpGaD
Tadalafil—Dyspnoea—Doxorubicin—kidney cancer	0.000109	0.000231	CcSEcCtD
Tadalafil—Somnolence—Doxorubicin—kidney cancer	0.000109	0.00023	CcSEcCtD
Tadalafil—Dyspepsia—Doxorubicin—kidney cancer	0.000107	0.000228	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—KRAS—kidney cancer	0.000106	0.00136	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TP53—kidney cancer	0.000106	0.00136	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000105	0.000223	CcSEcCtD
Tadalafil—Fatigue—Doxorubicin—kidney cancer	0.000105	0.000223	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—RAF1—kidney cancer	0.000105	0.00135	CbGpPWpGaD
Tadalafil—Constipation—Doxorubicin—kidney cancer	0.000104	0.000221	CcSEcCtD
Tadalafil—Pain—Doxorubicin—kidney cancer	0.000104	0.000221	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—IL2—kidney cancer	0.000104	0.00133	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000102	0.00132	CbGpPWpGaD
Tadalafil—Gastrointestinal pain—Doxorubicin—kidney cancer	9.99e-05	0.000212	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTT1—kidney cancer	9.79e-05	0.00126	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CA—kidney cancer	9.72e-05	0.00125	CbGpPWpGaD
Tadalafil—Urticaria—Doxorubicin—kidney cancer	9.7e-05	0.000206	CcSEcCtD
Tadalafil—Abdominal pain—Doxorubicin—kidney cancer	9.65e-05	0.000205	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—IL2—kidney cancer	9.43e-05	0.00121	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—TP53—kidney cancer	9.41e-05	0.00121	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—PTGS1—kidney cancer	9.18e-05	0.00118	CbGpPWpGaD
Tadalafil—Hypersensitivity—Doxorubicin—kidney cancer	9e-05	0.000191	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—HIF1A—kidney cancer	8.99e-05	0.00115	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TSC2—kidney cancer	8.97e-05	0.00115	CbGpPWpGaD
Tadalafil—Asthenia—Doxorubicin—kidney cancer	8.76e-05	0.000186	CcSEcCtD
Tadalafil—Pruritus—Doxorubicin—kidney cancer	8.64e-05	0.000183	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—KDR—kidney cancer	8.6e-05	0.0011	CbGpPWpGaD
Tadalafil—Diarrhoea—Doxorubicin—kidney cancer	8.35e-05	0.000177	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	8.3e-05	0.00107	CbGpPWpGaD
Tadalafil—Dizziness—Doxorubicin—kidney cancer	8.07e-05	0.000171	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—KIT—kidney cancer	7.92e-05	0.00102	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—APC—kidney cancer	7.92e-05	0.00102	CbGpPWpGaD
Tadalafil—Vomiting—Doxorubicin—kidney cancer	7.76e-05	0.000165	CcSEcCtD
Tadalafil—Rash—Doxorubicin—kidney cancer	7.7e-05	0.000163	CcSEcCtD
Tadalafil—Dermatitis—Doxorubicin—kidney cancer	7.69e-05	0.000163	CcSEcCtD
Tadalafil—Headache—Doxorubicin—kidney cancer	7.65e-05	0.000162	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—MAPK3—kidney cancer	7.58e-05	0.000974	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—POMC—kidney cancer	7.54e-05	0.000968	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—BRAF—kidney cancer	7.44e-05	0.000956	CbGpPWpGaD
Tadalafil—Nausea—Doxorubicin—kidney cancer	7.25e-05	0.000154	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—MAPK1—kidney cancer	7.22e-05	0.000927	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CA—kidney cancer	6.9e-05	0.000886	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—KRAS—kidney cancer	6.82e-05	0.000876	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTP1—kidney cancer	6.79e-05	0.000872	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	6.69e-05	0.00086	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CA—kidney cancer	6.26e-05	0.000804	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTM1—kidney cancer	6.24e-05	0.000801	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RAF1—kidney cancer	6.22e-05	0.000798	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RELA—kidney cancer	6.19e-05	0.000795	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	6.15e-05	0.00079	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ERBB2—kidney cancer	6.15e-05	0.00079	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MTOR—kidney cancer	6.07e-05	0.00078	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	5.91e-05	0.00076	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	5.83e-05	0.000749	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN1B—kidney cancer	5.69e-05	0.000732	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL2—kidney cancer	5.57e-05	0.000716	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCND1—kidney cancer	5.43e-05	0.000698	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—JUN—kidney cancer	5.42e-05	0.000696	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CTNNB1—kidney cancer	5.38e-05	0.000691	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTEN—kidney cancer	5.24e-05	0.000674	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ACY1—kidney cancer	5.2e-05	0.000668	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—VEGFA—kidney cancer	4.74e-05	0.000608	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MAPK3—kidney cancer	4.48e-05	0.000576	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PDHB—kidney cancer	4.42e-05	0.000568	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—POMC—kidney cancer	4.41e-05	0.000566	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MYC—kidney cancer	4.36e-05	0.00056	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MAPK1—kidney cancer	4.26e-05	0.000548	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CCBL1—kidney cancer	4.16e-05	0.000534	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—KRAS—kidney cancer	4.03e-05	0.000517	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CA—kidney cancer	3.7e-05	0.000475	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPAT—kidney cancer	3.6e-05	0.000463	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GLIPR1—kidney cancer	3.6e-05	0.000463	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TP53—kidney cancer	3.58e-05	0.00046	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—APRT—kidney cancer	3.35e-05	0.000431	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—FH—kidney cancer	3.35e-05	0.000431	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GPC3—kidney cancer	3.15e-05	0.000405	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CA2—kidney cancer	3.07e-05	0.000394	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALAD—kidney cancer	2.99e-05	0.000384	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ST3GAL2—kidney cancer	2.92e-05	0.000375	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.85e-05	0.000366	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.73e-05	0.000351	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PGK1—kidney cancer	2.73e-05	0.000351	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LDHB—kidney cancer	2.68e-05	0.000344	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CA9—kidney cancer	2.32e-05	0.000298	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CRABP1—kidney cancer	1.98e-05	0.000254	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ITPR2—kidney cancer	1.84e-05	0.000236	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ACHE—kidney cancer	1.67e-05	0.000215	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTT1—kidney cancer	1.67e-05	0.000215	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SCARB1—kidney cancer	1.59e-05	0.000204	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTGS1—kidney cancer	1.57e-05	0.000202	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PSMD7—kidney cancer	1.54e-05	0.000198	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—BCHE—kidney cancer	1.46e-05	0.000187	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.44e-05	0.000185	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.39e-05	0.000179	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTP1—kidney cancer	1.16e-05	0.000149	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCB1—kidney cancer	1.1e-05	0.000141	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTM1—kidney cancer	1.07e-05	0.000137	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.01e-05	0.00013	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—POMC—kidney cancer	7.54e-06	9.69e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTGS2—kidney cancer	6.01e-06	7.73e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTEN—kidney cancer	5.24e-06	6.74e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.7e-06	4.75e-05	CbGpPWpGaD
